Instylla announces enrollment of initial patient in the prospective multicenter “HALT” Study
Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the enrollment of the first patient in the HALT Study[i] for the treatment of peripheral arterial bleeds at MemorialCare Long Beach Medical Center. The HALT study is a Prospective, Multicenter Single-Arm Study to Evaluate the Safety Read More









